Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected IndividualsBNT162b2 mRNA 백신에 대한 강력한 항체 반응은 이전에 감염된 개인의 경우 첫 번째 접종 후 일주일 이내에, 감염되지 않은 개인의 경우 두 번째 접종 후 발생Immunology Published on 2021-08-262022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료법, [키워드] acquired immunity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody Anti-spike anti-spike and anti-nucleocapsid antibodies antibody Antibody Response Antibody responses Antibody titre antibody titres Blood blood sample Blood samples BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine collected conducted coronavirus coronavirus disease COVID-19 exposure to first dose FIVE genders HCW HCWs Health care Health care worker immunisation Immunity increase in Incubation period individual infected individuals Kinetics mRNA vaccine occurred offer pandemic path Patient respiratory response restrict viral replication Result robust SARS-CoV-2 second second dose second vaccination serological analysis severe acute respiratory syndrome Coronavirus Severity of disease Spike protein the spike protein titre Trigger vaccinated individual vaccinated individuals vaccination Viral viral replication virus was performed Week [DOI] 10.3389/fimmu.2021.722766 PMC 바로가기 [Article Type] Immunology
Inhibition of elastase enhances the adjuvanticity of alum and promotes anti–SARS-CoV-2 systemic and mucosal immunity엘라스타제의 억제는 명반의 면역증강을 강화하고 항-SARS-CoV-2 전신 및 점막 면역을 촉진합니다.423 Published on 2021-08-242022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 진단, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adjuvanticity alum alum adjuvant antibodies antibody Antibody Response Antibody responses Antigen Blood bloodstream blunt CD4 Cell-mediated immunity coronavirus COVID-19 patients Efficacy Elastase ENhance epitope Epitopes follicular help identify IgA antibodies IgA antibody IL-1 Immunity immunization Immunoglobulin IMPROVE induce inhibition inhibitor injected innate response interleukin investigated lack magnitude mice mucosal mucosal immunity mucosal route mucosal secretion mucosal tissue mucosal tissues myeloid cells neutrophil Neutrophil elastase neutrophil elastase inhibitor Neutrophils pharmacological promote protective antibodies Protective antibody Protein Protein subunit protein-based vaccine recruitment regulate response responses SARS-CoV-2 SARS-CoV-2 spike protein sera Serine serine protease serum antibody serum IgG severe acute respiratory syndrome Coronavirus SIgA Significance Spike protein stimulate subunit Support suppression T cell T cell responses T helper Tfh Th1 Th2 the spike protein vaccination Vaccine Vaccines [DOI] 10.1073/pnas.2102435118 PMC 바로가기 [Article Type] 423
Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patientsSARS-CoV-2에 대한 체액성 면역의 동적 지형 매핑은 중요한 COVID-19 환자의 생존과 관련된 비구조적 단백질 항체를 식별합니다Article Published on 2021-08-172022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] MERS, SARS, 바이오마커, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody Antibody Response Antibody responses binding epitope clinical variable clinical variables Cohort comprehensive analysis coronavirus correlation COVID-19 COVID-19 pathogenesis COVID-19 severity Critical critical COVID-19 patient diagnostics dynamic epitope Epitopes help high mortality high mortality rate humoral immune response Humoral immunity identify IgG antibodies IgG antibody IgM and IgG IgM antibodies IgM antibody immunogenic independent Infectious diseases innate immune response longitudinal analysis Microarray non-structural protein nonstructural protein nonstructural proteins Nsp3 Nsps nucleocapsid ORF3a Patient patients peptide peptide-based performed polyprotein Prognosis Proteases Protein respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 proteins SARS-CoV-2 proteome SARS-CoV-2 replication serum serum sample serum samples severe acute respiratory syndrome Coronavirus severity spike structural protein structural proteins survival therapy Transcription Treatment with COVID-19 [DOI] 10.1038/s41392-021-00718-w PMC 바로가기 [Article Type] Article
Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral ImmunitySARS-CoV-2 감염 중 COVID-19 증상의 발생은 체액 면역 약화를 정의합니다Immunology Published on 2021-08-162022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, [키워드] age antibody Antibody Response Antibody responses Antigen Asymptomatic asymptomatic individual Asymptomatic individuals asymptomatic infections body weight both groups collective/herd immunity correlated COVID-19 COVID-19 patients declined detectable Endemic enrolled Humoral immunity IgG IgG antibodies IgG response IgG responses IgM IgM response IgM responses Immunity immunization Immunoglobulin Immunoglobulin G implication in both groups individual Infection mounted neutralizing capacity nucleoprotein occur Plasma level Plasma levels Prevalence question raising SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2-specific IgG Sex side specific IgG antibodies subsequent Surveillance symptomatic symptomatic and asymptomatic symptomatic patient Symptomatic patients Symptoms the SARS-CoV-2 Viral viral spike Wuhan Wuhan, China [DOI] 10.3389/fimmu.2021.722027 PMC 바로가기 [Article Type] Immunology
Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand태국의 COVID-19 환자에서 SARS-COV-2의 재조합 수용체-결합 단백질 (RBD)에 대한 항체 반응의 클래스 및 서브 클래스를 특성화하기위한 종단 분석Research Article Published on 2021-08-102022-09-10 Journal: PLoS ONE [Category] MERS, SARS, 진단, 치료기술, 치료제, [키워드] acute phase acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis angiotensin Angiotensin-converting enzyme antibody Antibody assays Antibody Response Antibody responses contribute convalescent sera convalescent serum coronavirus coronavirus disease Coronavirus disease 2019 correlation COVID-19 COVID-19 patient COVID-19 patients Dengue fever detect domain ELISA ELISAs febrile healthy individual healthy individuals highest Host Human human immune response IgA IgG IgG level IgG levels IgG subclasse IgG subclasses IgG1 IgG3 IgM immune responses Infection Influenza Interpretation investigated leptospirosis longitudinal median molecular assays murine murine typhus natural infection ORF1ab ORF1ab gene outbreak Patient patients patients with COVID-19 Protein RBD RBD antigen reactivity respiratory RT-PCR SARS-CoV-2 SARS-COV-2 infection sera serological assays serum serum sample serum samples severe acute respiratory syndrome Coronavirus significantly higher Spike protein target tested Therapeutics tropical typhus Viral Viral detection viral spike protein [DOI] 10.1371/journal.pone.0255796 PMC 바로가기 [Article Type] Research Article
Immunity to SARS‐CoV‐2 induced by infection or vaccination감염 또는 예방접종으로 유발된 SARS-CoV-2에 대한 면역Review Published on 2021-08-052022-09-10 Journal: Journal of internal medicine [Category] MERS, SARS, 변종, 진단, [키워드] antibody Antibody responses Arm arms race B cell B cells clearance Community concerning COVID‐19 COVID‐19 Critical effective exceptional highlight immune response immune responses in viral Infection Mutation Neutralizing antibodies neutralizing antibody pandemic performed population immunity protective immunity researcher response responses against SARS‐CoV‐2 SARS‐CoV‐2 Seroprevalence significant difference vaccination Vaccine Vaccines variant Viral viral clearance viral variant Viral variants virus viruses [DOI] 10.1111/joim.13372 PMC 바로가기 [Article Type] Review
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers개별 의료 종사자의 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 항체 반응의 기간, 역학 및 결정인자Article Published on 2021-08-022022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, 치료기술, 치료법, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody anti-Spike IgG anti-spike IgG levels antibody antibody half-life antibody levels Antibody Response Antibody responses Asian association Bayesian can be used Chain Reaction coronavirus coronavirus 2 COVID-19 credibility interval CrI detectable determinant Duration Dynamics estimate example faster future infection half-lives HCW HCWs healthcare worker IgG IgG level Immunity Immunoglobulin Immunoglobulin G Increasing increasing age individual interval Linear model longitudinal Longitudinal studies longitudinal study median nucleocapsid IgG polymerase chain polymerase chain reaction positive positive PCR test positive result Positive test proportion Reinfection remained required respiratory response responses risk SARS-CoV-2 self-reported symptom serology seropositive severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 survival survival analysis Symptom the mean was used were used without symptoms worker [DOI] 10.1093/cid/ciab004 PMC 바로가기 [Article Type] Article
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency항체 결핍 환자에서 SARS-CoV-2에 대한 강력한 항체 및 T 세포 반응Article Published on 2021-08-012022-09-11 Journal: Journal of Clinical Immunology [Category] MERS, SARS, 변종, 진단, 치료법, [키워드] adaptive Adaptive immune response antibody Antibody deficiency Antibody Response Antibody responses candidate vaccine cellular immunity characterized Clinical course Cohort common variable immunodeficiency common variable immunodeficiency. Control controls convalescent COVID-19 deficiency demonstrated described Diagnosis donors evaluated healthy humoral Humoral immunity immune immune deficiency immune response Immunity Immunocompromised patient Immunocompromised patients immunodeficiency in some Inborn errors increased risk infected with SARS-CoV-2 Jackson Lancet Long Longevity NAT no significant difference nucleocapsid onset of symptoms Patient patients Pediatric patient Pediatric patients Prolonged infection response robust SARS-CoV-2 significant difference Spike protein Spike proteins structural protein structural proteins T cell T cell response T cell responses the timing Variability were assessed while [DOI] 10.1007/s10875-021-01046-y PMC 바로가기 [Article Type] Article
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia만성 림프구 백혈병 환자에서 제 1 및 제 2 코비드 -19 백신 접종 후 항체 반응Clinical Trial Published on 2021-07-302022-08-09 Journal: Blood Cancer Journal [Category] 임상, 진단, [키워드] Adaptive immunity Antibody Response Antibody responses Antibody titre antibody titres B-cell blood sample Blood samples BNT162b2 BNT162b2 mRNA vaccine booster vaccines BTK inhibitor BTK inhibitors ChAdOx1 Chronic lymphocytic leukaemia clinical risk CLL COVID-19 vaccines detectable dried blood spot Dried blood spots extended interval failure Filter Paper generate healthy donor healthy donors IgA deficiency Immunosuppression Multivariate analysis offer Patient profile remained SARS-COV-2 infection second vaccination Severe infection spike-specific antibody response Spike-specific antibody responses Support the antibody response the patient titre titres Translational research Treatment utility vaccination Vaccination strategy Vaccine venepuncture [DOI] 10.1038/s41408-021-00528-x PMC 바로가기 [Article Type] Clinical Trial
Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals혈청 양성 및 혈청 형성 개인에서 SARS-CoV-2 mRNA 백신 투여 동안 체액 면역 반응Research Article Published on 2021-07-262022-09-01 Journal: BMC Medicine [Category] SARS, 진단, [키워드] administration antibody antibody level antibody levels Antibody Response Antibody responses Antibody titers approved binding Binding assays BNT162b2 caused comparable coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated dose doses Efficacy epitope Epitopes first vaccination global pandemic guide had no high resolution humoral immune responses IgA IgG IgM antibody immune immune response immune responses immunization immunodominant individual Infection mapped Messenger RNA mRNA mRNA vaccine peptide peptides Pfizer-BioNTech protein antigen regimens Result S1 and S2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralizing antibody SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 viral SARS-CoV-2 virus seronegative seropositive seropositive individual seropositive individuals significantly higher single dose specificity Spike protein subunit supplementary material Support the antibody response the SARS-CoV-2 the SARS-CoV-2 virus USA vaccination Vaccine Viral viral infection while [DOI] 10.1186/s12916-021-02055-9 PMC 바로가기 [Article Type] Research Article